Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-268-6 | CAS number: 1317-37-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Remarks:
- combined repeated dose and reproduction / developmental screening
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2004
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study was conducted according to GLP and valid methods, therefore it is considered relevant, reliable and adequate for classification. The data are from a secondary source of reliable instance and the level of detail was high.
Data source
Reference
- Reference Type:
- other: OECD SIDS
- Title:
- Unnamed
- Year:
- 2 004
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Iron dichloride
- EC Number:
- 231-843-4
- EC Name:
- Iron dichloride
- Cas Number:
- 7758-94-3
- IUPAC Name:
- iron(2+) dichloride
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- - Name of test material (as cited in study report): : Iron dichloride
- Molecular formula (if other than submission substance): Cl2-Fe
- Molecular weight (if other than submission substance): 126.7516
- Smiles notation (if other than submission substance): [Fe](Cl)Cl
- InChl (if other than submission substance): 1S/2ClH.Fe/h2*1H;/q;;+2/p-2
- Structural formula attached as image file (if other than submission substance): See Fig.
- Substance type: Inorganic monoconstituent substance
- Physical state: Powder
- Analytical purity: 98 %
- Lot/batch No.: Sigma-Aldrich Corporation, LOT No. – 14330TA
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 8 weeks
- Weight during the study: 269.23 – 302.18 g for males and 191.34 –221.60 g for females
- Fasting period before study: No data
Administration / exposure
- Route of administration:
- oral: gavage
- Duration of treatment / exposure:
- 42 days for male animals and 42 to 54 days for female animals
- Frequency of treatment:
- Daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 125 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 250 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 70 animals for each sex in the main test: per dose group as follows G0:20M + 20 F, G1:15M + 15 F, G3:15M + 15F, G4:20M+ 20F
10 animals (5 males + 5 females) from G1 (0 mg/kg bw/day) and from G4 (500 mg/kg bw/day) groups were allocated as recovery groups. - Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale: In the preliminary tests all male rats in 1000 mg/kg bw/day treatment group were dead. For female rats, one rat was dead at the same dose level. Therefore, 500 mg/kg bw/day was chosen as the maximum dosage.
- Rationale for selecting satellite groups: 10 animals (5 males + 5 females) from G1 (0 mg/kg bw/day) and from G4 (500 mg/kg bw/day) groups were allocated as recovery groups.
- Post-exposure recovery period in satellite groups: 14 days
Examinations
- Observations and examinations performed and frequency:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Clinical symptoms were observed once a day and once a week in detail.
- The death rate was observed twice a day.
BODY WEIGHT: Yes
- Time schedule for examinations: The body weights were measured once a week and right before the necropsy except mating period, but for pregnant females, it was measured on day 0, 7, 14, 20 of gestation period, date of delivery, and 4 days after the delivery.
FOOD CONSUMPTION AND COMPOUND INTAKE ):
- Consumption rate was measured once a week except during mating period.
OPHTHALMOSCOPIC EXAMINATION: No data
HAEMATOLOGY: Yes
- Time schedule for collection of blood: 18 hrs before necropsy.
- Anaesthetic used for blood collection: Yes ,ether
- Animals fasted: Yes
- How many animals: 5 males and 5 females from each test group (randomly selected)
- Parameters examined:
total erythrocyte count (RBC),
hemoglobin concentration (HEG),
hematocrit (HCT),
mean cell volume (MCV),
mean cell hemoglobin (MCH),
mean cell hemoglobin concentration (MCHC),
total leucocyte count (WBC),
platelet (PLT),
neutrophils (NEU),
eosinophils (EOS),
basophils (BASO),
lymphocytes (LYM),
monocytes (Mono).
After blood collection, sera were separated using a centrifuge to measure prothrombin time (PT) and activated partial thromboplastin time (APTT). Metheamoglobin (MH) was also analyzed.
CLINICAL CHEMISTRY: Yes
- Parameters examined:
alanine,
aminotransferase,
aspartate aminotransferase,
blood urea nitrogen,
creatinine,
total protein,
albumin,
sodium,
potassium,
triglycerides,
glucose,
phosphorus,
calcium,
cholinesterase.
Cholinesterase II activity was measured with S-butyrylthilcholine iodide as a substrate.
URINALYSIS: Yes
- Five males and five females were randomly selected from each test group.
- Following seven items were tested; color, specific gravity, pH, glucose, protein, leukocyte, erythrocyte.
NEUROBEHAVIOURAL EXAMINATION: Yes
- Test for sensory organ: Five males and five females were randomly selected from each test group. Both auricle reflex test and corneal reflex test were performed before necropsy.
- Motor function test: Five males and five females were randomly selected from each test group for traction test. This test was performed before necropsy. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table)
- Organ weight: testes, epididymides(all males), liver, kidney, adrenal, thymus, spleen, brain and heart (5 male and 5 female animals from each test group).
HISTOPATHOLOGY: Yes
- Fixation: 21 tissues were preserved in 10 % buffered neutral formalin solution for histopathologic tests: brain, pituitary, spinal cord, heart, lung, trachea, stomach, ileum, liver, colon, spleen, thyroids, thymus, adrenals, kidneys, urinary bladder, sciatic nerve, bone marrow, uterus, ovaries and lymph node. Testes and epididymides were fixed in bouin’s fixative. - Statistics:
- Homogeneity of variance was evaluated using Levene’s test in terms of body weight, food and water consumption, biochemical test of blood and organ weight. When the assumption of homogeneity of variance was met, ANOVA was used. If significant result was observed, Dunnett’s test was used. When the assumption of heterogeneity of variance was met, appropriate data transformation was carried out, then Levene’s test was performed on re-transformed data. If significant result was observed, Dunnett’s test was used.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- reversible decrease in locomotion activity at 500 mg/kg bw in females more than males
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- No death was observed for male animals. Three female rats in 500 mg/kg bw/day treatment group were found dead on the day 38, 46 and 51 of administration.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- decreased at 250 and 500 mg/kg bw/day male groups; no significant changes in females except on day 7 of premating period and the day 4 of lactation period
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- increased in 500 mg/kg bw dosed males and females
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- increased liver weights at 250 males and 500 mg/kg b.w. males and females; increased adrenal glands weights in 250 and 500 mg/kg b.w. dosed males
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- severe diffuse hemorrhagic grandular stomach/distension of stomach in dead animals, and diffuse black colored liver and hemorrhage with diffuse black pigmentation in 500 mg/kg males; mass of mesenteric lymph node in 500 mg/kg dosed females
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- hemosiderin deposit of hepatocyte and granular, hyperplasia of zona fasciculate in adrenal cortex, hyperkeratosis of forestomach, hemosiderin deposit of grandular stomach, neutrophil infiltration of submusoca in 500 mg/kg dosed males and less in females
- Details on results:
- CLINICAL SIGNS, BEHAVIOUR AND MORTALITY
No death was observed for male animals. Three female rats in 500 mg/kg bw/day treatment group were found dead on the day 38, 46 and 51 of administration.
Clinical signs such as blackish stool and salivation were observed in both the control and the treated groups. In the early stages of administration, cases of decrease in locomotion activity were found in 500 mg/kg bw/day groups of both sexes, but these were recovered to normal states. The female rats were more sensitively affected than the male rats in locomotion activity decrease, paleness, emaciation and soiled perineal region. However, these symptoms were reversible within the test period.
BODY WEIGHT AND WEIGHT GAIN
The rate of body weight gain was significantly decreased in 250 and in 500 mg/kg bw/day male groups. For females, there was no significant changes except on the day 7 of pre-mating period and the day 4 of lactation period. Further, no dose-dependent changes were shown.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)
There was no significant difference between the control and the treated groups, and no dose-related change was observed in both sexes.
WATER CONSUMPTION (See Table 1 & 2)
In 500 mg/kg bw/day treatment group, the amount of water consumption was increased for both male and female animals.
HAEMATOLOGY
Statistically significant differences were found in mean cell volume (MCV), eosinophils (EOS) and platelet (PLT). But these were within the biologically normal range and no dose dependent changes were evident.
CLINICAL CHEMISTRY
Statistically significant differences were found in cholinesterase (CS), and triglycerides (TG). But these were within the biologically normal range and no dose dependent changes were evident.
URINALYSIS
There were no specific findings.
NEUROBEHAVIOUR
- Sensory reflex test: Both auricle reflex test and corneal reflex test were performed evaluating sensory reflex; no specific reaction was observed in comparison with the control group.
- Motor function test: Significant decrease was observed in female 125 and 500 mg/kg bw/day treatment groups. But these decreased values were higher than male control group since the mean value of female control group was higher than the male control group.
There was no significant result in female 250 mg/kg bw/day group and all male rats. Because there were no dose-dependent changes, motor function was not considered to be affected by iron dichloride.
ORGAN WEIGHTS (See Table 3 & 4)
Both absolute and relative weights of liver were increased in 250 and 500 mg/kg bw/day male groups and in 500 mg/kg bw/day female group. Also, for male rats, absolute adrenal glands weights were increased in 500 mg/kg bw/day group, and relative adrenal glands weights were increased in 250 and in 500 mg/kg bw/day group. Because of hemosiderin deposit in hepatocyte and hyperplasia of zona fasciculate in adrenal cortex, the increased weights of liver and adrenla glands were influnced by the test substance. In 125 mg/kg bw/day male group, liver weight did not differ from the control group, but adrenal glands weights were decreased as compared to the control group. For thymus, absolute weight was decreased in female 125 and 500mg/kg bw/day groups, and relative weight was decreased in 500 mg/kg bw/day group. However, these changes were considered to be individual variations and not due to the test substance.
GROSS PATHOLOGY
Diaphragmatic nodules of liver were sporadically noted in the control and the treated groups. It is a congenital malformation, which is a morphological change and doesn’t have physiological effects.
The following necropsy opinions were caused by the test substance; severe diffuse hemorrhagic grandular stomach and severe distension of stomach in dead animals, and diffuse black colored liver and hemorrhage with diffuse black pigmentation in scheduled necropsy of 500 mg/kg bw/day male group. For females, a case of mass of mesenteric lymph node was observed in 500 mg/kg bw/day group.
HISTOPATHOLOGY: NON-NEOPLASTIC
For 500 mg/kg bw/day groups of both sexes, hemosiderin deposit of hepatocyte and grandular, hyperplasia of zona fasciculate in adrenal cortex, hyperkeratosis of fore stomach, hemosiderin deposit of grandular stomach, neutrophil infiltration of submucosa were observed. These conditions were induced by the test substance and were weaker in females. There was no specific findings in the recovery groups. In case of dead rats, due to severe villous atrophy of fore stomach, gastric function was abnormal. Therefore, it was concluded that female rats were dead by a physical irritancy of test substance.
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 125 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: overall effects
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 250 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: overall effects
Target system / organ toxicity
- Critical effects observed:
- no
- Lowest effective dose / conc.:
- 250 mg/kg bw/day (actual dose received)
- System:
- hepatobiliary
- Organ:
- adrenal glands
- liver
- stomach
Any other information on results incl. tables
Table 1. Water consumption of male rats (mL/animal/day)
Group/Dose (mg/kg) |
Day after treatment |
||||
|
0 |
6 |
13 |
40 |
|
G1 0 |
Mean S.D. N |
30.06 4.03 10 |
35.87 6.65 10 |
41.05 10.22 10 |
44,36 16.35 10 |
G2 125 |
Mean S.D. N |
29.51 8.62 8 |
35.36 5.05 8 |
39.78 9.20 8 |
43.42 5.66 8 |
G3 250 |
Mean S.D. N |
31.34 4.56 8 |
33.73 4.74 8 |
39.07 8.96 8 |
36.78 5.00 8 |
G4 500 |
Mean S.D. N |
31.93 3.48 10 |
45.29 * 7.56 10 |
57.04 * 12.20 10 |
38.10 * 23.08 10 |
N: Number of cages
*: Statistical significance was observed.
Table 2. Water consumption of female rats (mL/animal/day)
Group/ Dose (mg/kg) |
Premating period |
Gestation period |
Lactation period |
|||||||
0 |
6 |
13 |
0 |
6 |
13 |
20 |
0 |
3 |
||
G1 0
|
Mean S.D. N |
54.98 9.06 10 |
53.21 13.90 10 |
61.45 9.61 10 |
31.98 4.91 11 |
39.04 7.17 11 |
44.36 9.54 11 |
48.85 9.97 11 |
41.26 8.18 11 |
56.25 22.95 11 |
G2 125
|
Mean S.D. N |
53.43 16.89 8 |
52.14 18.55 8 |
60.49 19.20 8 |
30.06 4.64 12 |
35.91 7.36 12 |
41.67 9.55 12 |
48.02 9.69 12 |
44.80 7.13 12 |
65.99 20.21 12 |
G3 250
|
Mean S.D. N |
58.21 10.44 8 |
58.00 10.59 8 |
68.64 6.92 8 |
32.59 6.35 14 |
40.41 9.47 14 |
44.87 6.56 14 |
50.43 8.73 14 |
47.45 9.27 14 |
66.83 15.07 14 |
G4 500
|
Mean S.D. N |
58.16 8.14 10 |
81.04* 10.68 10 |
82.60* 11.51 10 |
36.10 6.91 10 |
47.62 8.04 10 |
47.20 10.53 10 |
65.01* 13.43 10 |
51.81* 12.22 10 |
66.33 26.55 10 |
N: Number of cages (pre-mating period), Number of animals (Gestation period & Lactation period)
*: Statistical significance was observed.
Table 3. Absolute organ weights of males (group mean)
Dose (mg/kg) |
0 |
125 |
250 |
500 |
Brain (g) Heart (g) Liver (g) Spleen (g) Thymus (g) Lt. Kidney (g) Rt. Kidney (g) Lt. Adrenal gland (g) Rt. Adrenal gland (g) Lt. Testes (g) Rt. Testes (g) Lt. Epididymis (g) Rt. Epididymis (g) |
2.11 1.39 11.32 0.90 0.49 1.41 1.44 27.00 24.66 1.70 1.70 0.60 0.60 |
2.01 1.34 11.96 1.03 0.49 1.44 1.45 26.64 24.76 1.73 1.76 0.61 0.62 |
2.02 1.30 13.30* 1.03 0.47 1.42 1.46 28.90 28.90 1.70 1.92 0.62 0.60 |
1.95 1.25 14.04* 0.89 0.36 1.36 1.39 33.32* 34.26* 1.73 1.77 0.59 0.58 |
Number of animals: 5/group
*: Statistical significance was observed.
Table 4. Absolute organ weight of females (group mean)
Dose (mg/kg) |
0 |
125 |
250 |
500 |
Brain (g) Heart (g) Liver (g) Spleen (g) Thymus (g) Lt. Kidney (g) Rt. Kidney (g) Lt. Adrenal gland (g) Rt. Adrenal gland (g) |
1.93 1.03 9.77 0.86 0.34 0.89 0.88 3.50 3.47 |
1.97 0.97 9.81 0.73 0.23* 0.88 0.89 3.53 3.42 |
1.91 0.96 10.22 0.72 0.27 0.86 0.86 3.85 3.46 |
1.93 0.98 11.36* 0.74 0.25* 0.94 0.96 3.95 3.78 |
Number of animals : 5/group
*: Statistical significance was observed.
Applicant's summary and conclusion
- Conclusions:
- By the particular test results such as the rate of body weight gain, water consumption, organ weights, necropsy, and histopathology, NOAEL values were determined to 125 mg/kg bw/day for males and 250 mg/kg bw/day for females.
- Executive summary:
Repeated dose toxicity of Iron dichloride (98% purity) was tested in male and female Sprague-Dawley rats by daily oral gavage at dose levels of 0, 125, 250 and 500 mg/kg bw/ day for 42 days (male rats) and 42 to 54 days (female rats). 15 animals per sex per dose level were used and in the high and low dose group additional 5 animals per sex were allocated as (14 days) recovery groups. No death was observed for male animals. Three female rats in the high dose treatment group were found dead on the day 38, 46 and 51 of administration. Clinical signs such as blackish stool and salivation were observed in both the control and the treated groups. In the early stages of administration, cases of decrease in locomotion activity were found in 500 mg/kg bw/day groups of both sexes, but these were recovered to normal states. The female rats were more sensitively affected than the male rats in locomotion activity decrease, paleness, emaciation and soiled perineal region. However, these symptoms were reversible within the test period.
The rate of body weight gain was significantly decreased in 250 and in 500 mg/kg bw/day male groups. For females, there was no significant changes except on the day 7 of pre-mating period and the day 4 of lactation period. Further, no dose-dependent changes were shown. There was no significant difference in food consumption between the control and the treated groups, and no dose-related change was observed in both sexes.
In 500 mg/kg bw/day treatment group, the amount of water consumption was increased for both male and female animals.
Statistically significant differences were found in mean cell volume (MCV), eosinophils (EOS), platelet (PLT), cholinesterase (CS) and triglycerides (TG). But these were within the biologically normal range and no dose dependent changes were evident. There were no specific findings in the urinalysis.
Both auricle reflex test and corneal reflex test were performed evaluating sensory reflex; no specific reaction was observed in comparison with the control group. Significant decrease was observed in female 125 and 500 mg/kg bw/day treatment groups. But these decreased values were higher than male control group since the mean value of female control group was higher than the male control group.
There was no significant result in motor function test in female 250 mg/kg bw/day group and all male rats. Because there were no dose-dependent changes, motor function was not considered to be affected by iron dichloride.
Both absolute and relative weights of liver were increased in 250 and 500 mg/kg bw/day male groups and in 500 mg/kg bw/day female group. Also, for male rats, absolute adrenal glands weights were increased in 500 mg/kg bw/day group, and relative adrenal glands weights were increased in 250 and in 500 mg/kg bw/day group. Because of hemosiderin deposit in hepatocyte and hyperplasia of zona fasciculate in adrenal cortex, the increased weights of liver and adrenal glands were influenced by the test substance. In 125 mg/kg bw/day male group, liver weight did not differ from the control group, but adrenal glands weights were decreased as compared to the control group. For thymus, absolute weight was decreased in female 125 and 500mg/kg bw/day groups, and relative weight was decreased in 500 mg/kg bw/day group. However, these changes were considered to be individual variations and not due to the test substance.
Diaphragmatic nodules of liver were sporadically noted in the control and the treated groups. It is a congenital malformation, which is a morphological change and doesn’t have physiological effects.
The following necropsy opinions were caused by the test substance; severe diffuse hemorrhagic grandular stomach and severe distension of stomach in dead animals, and diffuse black colored liver and hemorrhage with diffuse black pigmentation in scheduled necropsy of 500 mg/kg bw/day male group. For females, a case of mass of mesenteric lymph node was observed in 500 mg/kg bw/day group.
For 500 mg/kg bw/day groups of both sexes, hemosiderin deposit of hepatocyte and grandular, hyperplasia of zona fasciculate in adrenal cortex, hyperkeratosis of fore stomach, hemosiderin deposit of grandular stomach, neutrophil infiltration of submucosa were observed. These conditions were induced by the test substance and were weaker in females. There was no specific findings in
the recovery groups. In case of dead rats, due to severe villous atrophy of fore stomach, gastric function was abnormal. Therefore, it was concluded that female rats were dead by a physical irritancy of test substance.
By the particular test results such as the rate of body weight gain, water consumption, organ weights, necropsy, and histopathology, NOAEL values were determined to 125 mg/kg bw/day for males and 250 mg/kg bw/day for females.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.